医学创新论坛第84期

时间：2025年9月24日（周三）下午16:00

地点：首都医科大学基础科研楼北楼一层逸夫报告厅

主持人：

周欣

首都医学科学创新中心

报告人：

韩为东

教授

中国人民解放军总医院生物治疗科

报告题目：

Clinical exploration of innovative anti-tumor immunotherapy

摘要：

Introducing dual-target CART, epigenetically modified CART, and universal CART in the research of B-cell malignancies in the hematologic system; tumor GSL synthesis and immune escape from immunotherapy, as well as the development of universal CART based on similar principles applied in T-cell immune tolerance studies. Introducing epigenetic immune anti-tumor combination therapies. 

报告人简介：

Han Weidong, 55 years old, is a doctor of clinical medicine, chief physician of the Department of Biotherapy at the PLA General Hospital, professor, doctoral supervisor, one of the National Hundred Thousand Talents, a special expert of the State Council, and a leading talent in science and technology innovation in the capital. He is mainly engaged in the research on the mechanism of resistance to tumor treatment, the development of new technologies for tumor immunotherapy, and clinical translation. He has more than 20 national invention patents. He has published more than 180 SCI papers as the first author or corresponding author in academic journals such as JCO, Cell, Cell Res (2), Blood (2), Nature Cancer, CCR, NAR, JNCI, STTT (5), Nat Comm (2), JHO, CMI, Leukemia, Lancet Hematology, JCI, Mol Can, JEM, etc., with a cumulative impact factor of more than 1,700 points and an H index of 61 points. He has been cited 12,596 times. He has been rated as a highly cited scholar in clinical medicine in China by Elsevier for five consecutive years from 2020 to 2024. 

代表性论文：